Advertisement

Annals of Hematology

, Volume 92, Issue 7, pp 989–992 | Cite as

Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab

  • Huai-Cheng Huang
  • Ann-Lii Cheng
  • Chung-Wu Lin
  • Sung-Hsin Kuo
Letter to the Editor

Dear Editor,

Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT type) of the orbits accounts for 35–80 % of primary ocular adnexal lymphoma cases. The majority (85–90 %) of these patients present with localized disease and indolent behavior [1]. Although localized ocular adnexal MALT lymphoma is highly responsive to radiotherapy, immunotherapy, and chemotherapy, a local relapse with high-grade transformation (most histology, diffuse large B cell lymphoma (DLBCL)) was rarely found in this subgroup of patients, with a reported rate of 2–3 % [2, 3]. In addition, primary ocular MALT lymphoma with central nervous system (CNS) involvement or relapse is rare, with most relapses developing locally or with distant recurrence [1, 4, 5]. This paper presents a localized MALT lymphoma of the right ocular adnexa that achieved complete remission after immunochemotherapy and early development of relapsed transformed high-grade DLBCL of the CNS.

A 31-year-old man...

Keywords

Malt Lymphoma Central Nervous System Lymphoma Central Nervous System Relapse Intraocular Lymphoma Central Nervous System Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

No financial or other potential conflicts of interest exist for any of the authors.

References

  1. 1.
    Stefanovic A, Lossos IS (2009) Extranodal marginal zone lymphoma of the ocular adnexa. Blood 114:501–510PubMedCrossRefGoogle Scholar
  2. 2.
    Tanimoto K, Kaneko A, Suzuki S et al (2006) Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135–140PubMedCrossRefGoogle Scholar
  3. 3.
    Tanimoto K, Kaneko A, Suzuki S et al (2007) Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Jpn J Clin Oncol 37:337–344PubMedCrossRefGoogle Scholar
  4. 4.
    Zucca E, Conconi A, Pedrinis E et al (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489–2495PubMedCrossRefGoogle Scholar
  5. 5.
    Bayraktar S, Stefanovic A, Montague N et al (2010) Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol 89:1003–1009PubMedCrossRefGoogle Scholar
  6. 6.
    Isaacson PG (1999) Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36:139–147PubMedGoogle Scholar
  7. 7.
    Kuo SH, Chen LT, Wu MS et al (2007) Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. J Pathol 211:296–304PubMedCrossRefGoogle Scholar
  8. 8.
    Cheng AL, Yeh KH, Uen WC et al (1998) Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 82:1946–1951PubMedCrossRefGoogle Scholar
  9. 9.
    Paik JS, Cho WK, Lee SE et al (2012) Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Ann Hematol 91:1393–1401PubMedCrossRefGoogle Scholar
  10. 10.
    Du MQ (2007) MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematop 47:31–42PubMedCrossRefGoogle Scholar
  11. 11.
    Restrepo A, Raez LE, Byrne GE Jr et al (1998) Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog 9:269–273PubMedGoogle Scholar
  12. 12.
    Bayraktar S, Bayraktar UD, Stefanovic A et al (2011) Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol 152:72–80PubMedCrossRefGoogle Scholar
  13. 13.
    Antonini G, Cox MC, Montefusco E et al (2007) Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 81:197–199PubMedCrossRefGoogle Scholar
  14. 14.
    Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350–1356PubMedCrossRefGoogle Scholar
  15. 15.
    Batchelor TT, Grossman SA, Mikkelsen T et al (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929–930PubMedCrossRefGoogle Scholar
  16. 16.
    Tai WM, Chung J, Tang PL et al (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90:809–818PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Huai-Cheng Huang
    • 1
    • 3
  • Ann-Lii Cheng
    • 2
    • 3
    • 5
  • Chung-Wu Lin
    • 4
  • Sung-Hsin Kuo
    • 2
    • 3
    • 5
  1. 1.Department of Oncology, Yun-Lin BranchNational Taiwan University HospitalYun-LinTaiwan
  2. 2.Department of Internal MedicineNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  3. 3.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan
  4. 4.Department of PathologyNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  5. 5.Cancer Research CenterNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan

Personalised recommendations